Pharma Pulse: SOBI’s $1.5B Gout Acquisition Clears Pipeline; New Cholesterol Drug Lerochol Scores on Convenience

Dec 16, 10:30 AM

Headliner
Share
Subscribe
In today’s Pharma Pulse, SOBI strengthens its gout franchise by acquiring Arthrosi Therapeutics for up to $1.5 billion, securing the Phase III asset pozdeutinurad, and much more. 
Share
Subscribe
Next
Pharma Pulse: Amgen's Uplizna Secures CD19 Approval for Myasthenia Gravis, as Asthma Biologic Switches Highlight Efficacy Expectations Gap
Top episodes
Incorporating AI into Commercialization Plans
by Pharmaceutical Commerce
Overcoming Supply Chain Challenges
by Pharmaceutical Commerce
The Capabilities of a 3PL Provider
by Pharmaceutical Commerce